SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Marr, K. A. Articles by Boeckh, M. Search for Related Content PubMed PubMed Citation Articles by Marr, K. A. Articles by Boeckh, M. Related Collections Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 September 2000, Vol. 96, No. 6, pp. 2055-2061 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial Kieren A. Marr, Kristy Seidel, Monica A. Slavin, Raleigh A. Bowden, H. Gary Schoch, Mary E. D. Flowers, Lawrence Corey, and Michael Boeckh From the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA. Two randomized, placebo-controlled trials previously showed that fluconazole (400 mg/d) administered prophylactically decreases the incidence of candidiasis in blood and marrow transplant (BMT) recipients. However, there exists conflicting data regarding the optimal duration of fluconazole administration, specifically whether prophylaxis through acute graft-versus-host disease (GVHD) results in improved survival in allograft recipients. Reported here are the results of long-term follow-up and a detailed analysis of invasive candidiasis and candidiasis-related death in 300 patients who received fluconazole (400 mg/d) or placebo for 75 days after BMT at the Fred Hutchinson Cancer Research Center. Patients in both treatment arms were compared for survival, causes of death, and the incidence of invasive fungal infections early (less than 110 days) and late (more than 110 days) after BMT. After 8 years of follow-up, survival is significantly better in fluconazole recipients compared with placebo recipients (68 of 152 vs 41 of 148, P = .0001). The overall incidence of invasive candidiasis was increased in patients who received placebo compared with fluconazole (30 of 148 vs 4 of 152, P < .001). More patients who received placebo died with candidiasis early (13 of 148 vs 1 of 152, P = .001) and late (8 of 96 vs 1 of 121, P = .0068) after BMT. The incidence of severe GVHD involving the gut was higher in patients who did not receive fluconazole (20 of 143 vs 8 of 145, P = .02), and fewer patients who received fluconazole died with this complication. Thus, administration of fluconazole (400 mg/d) for 75 days after BMT appears to be associated with decreased gut GVHD, a persistent protection against disseminated candidal infections and candidiasis-related death, resulting in an overall survival benefit in allogeneic BMT recipients. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Michallet and J. I. Ito Approaches to the Management of Invasive Fungal Infections in Hematologic Malignancy and Hematopoietic Cell Transplantation J. Clin. Oncol., July 10, 2009; 27(20): 3398 - 3409. [Abstract] [Full Text] [PDF] O. A. Cornely, A. Bohme, D. Buchheidt, H. Einsele, W. J. Heinz, M. Karthaus, S. W. Krause, W. Kruger, G. Maschmeyer, O. Penack, et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology Haematologica, January 1, 2009; 94(1): 113 - 122. [Abstract] [Full Text] [PDF] C. D. Collins, J. J. Ellis, and D. R. Kaul Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia Am. J. Health Syst. Pharm., December 1, 2008; 65(23): 2237 - 2243. [Abstract] [Full Text] [PDF] O. A. Cornely, A. Bohme, D. Reichert, S. Reuter, G. Maschmeyer, J. Maertens, D. Buchheidt, M. Paluszewska, D. Arenz, U. Bethe, et al. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis J. Antimicrob. Chemother., April 1, 2008; 61(4): 939 - 946. [Abstract] [Full Text] [PDF] M. L. Sorror, B. E. Storer, D. G. Maloney, B. M. Sandmaier, P. J. Martin, and R. Storb Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia Blood, January 1, 2008; 111(1): 446 - 452. [Abstract] [Full Text] [PDF] V. Erard, K. A. Guthrie, C. Varley, J. Heugel, A. Wald, M. E. D. Flowers, L. Corey, and M. Boeckh One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation Blood, October 15, 2007; 110(8): 3071 - 3077. [Abstract] [Full Text] [PDF] M. L. Sorror, B. M. Sandmaier, B. E. Storer, M. B. Maris, F. Baron, D. G. Maloney, B. L. Scott, H. J. Deeg, F. R. Appelbaum, and R. Storb Comorbidity and Disease Status Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation J. Clin. Oncol., September 20, 2007; 25(27): 4246 - 4254. [Abstract] [Full Text] [PDF] K. Oshima, Y. Kanda, Y. Asano-Mori, N. Nishimoto, S. Arai, S. Nagai, H. Sato, T. Watanabe, N. Hosoya, K. Izutsu, et al. Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients J. Antimicrob. Chemother., August 1, 2007; 60(2): 350 - 355. [Abstract] [Full Text] [PDF] A. J. Ullmann, J. H. Lipton, D. H. Vesole, P. Chandrasekar, A. Langston, S. R. Tarantolo, H. Greinix, W. Morais de Azevedo, V. Reddy, N. Boparai, et al. Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease N. Engl. J. Med., January 25, 2007; 356(4): 335 - 347. [Abstract] [Full Text] [PDF] D. A. Enoch, H. A. Ludlam, and N. M. Brown Invasive fungal infections: a review of epidemiology and management options. J. Med. Microbiol., July 1, 2006; 55(Pt 7): 809 - 818. [Abstract] [Full Text] [PDF] C. Charlier, E. Hart, A. Lefort, P. Ribaud, F. Dromer, D. W. Denning, and O. Lortholary Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J. Antimicrob. Chemother., March 1, 2006; 57(3): 384 - 410. [Abstract] [Full Text] [PDF] A. Glasmacher, A. Prentice, M. Gorschluter, S. Engelhart, C. Hahn, B. Djulbegovic, and I. G.H. Schmidt-Wolf In Reply: J. Clin. Oncol., December 20, 2005; 23(36): 9429 - 9432. [Full Text] [PDF] M. L. Sorror, M. B. Maris, R. Storb, F. Baron, B. M. Sandmaier, D. G. Maloney, and B. Storer Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT Blood, October 15, 2005; 106(8): 2912 - 2919. [Abstract] [Full Text] [PDF] W. H. Kruger, J. Bohlius, O. A. Cornely, H. Einsele, H. Hebart, G. Massenkeil, S. Schuttrumpf, G. Silling, A. J. Ullmann, D. T. Waldschmidt, et al. Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology Ann. Onc., August 1, 2005; 16(8): 1381 - 1390. [Abstract] [Full Text] [PDF] R. Diaconescu, C. R. Flowers, B. Storer, M. L. Sorror, M. B. Maris, D. G. Maloney, B. M. Sandmaier, and R. Storb Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors Blood, September 1, 2004; 104(5): 1550 - 1558. [Abstract] [Full Text] [PDF] M. L. Sorror, M. B. Maris, B. Storer, B. M. Sandmaier, R. Diaconescu, C. Flowers, D. G. Maloney, and R. Storb Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities Blood, August 15, 2004; 104(4): 961 - 968. [Abstract] [Full Text] [PDF] D. Kaufman and K. D. Fairchild Clinical Microbiology of Bacterial and Fungal Sepsis in Very-Low-Birth-Weight Infants Clin. Microbiol. Rev., July 1, 2004; 17(3): 638 - 680. [Abstract] [Full Text] [PDF] D. J. Winston, R. T. Maziarz, and P. H. Chandrasekar Itraconazole versus Fluconazole for Antifungal Prophylaxis Ann Intern Med, April 6, 2004; 140(7): 581 - 582. [Full Text] [PDF] M. Karthaus, O. A. Cornely, and A. J. Ullmann Itraconazole versus Fluconazole for Antifungal Prophylaxis Ann Intern Med, April 6, 2004; 140(7): 579 - 580. [Full Text] [PDF] K. A. Marr, F. Crippa, W. Leisenring, M. Hoyle, M. Boeckh, S. A. Balajee, W. G. Nichols, B. Musher, and L. Corey Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants Blood, February 15, 2004; 103(4): 1527 - 1533. [Abstract] [Full Text] [PDF] A. Glasmacher, A. Prentice, M. Gorschluter, S. Engelhart, C. Hahn, B. Djulbegovic, and I. G.H. Schmidt-Wolf Itraconazole Prevents Invasive Fungal Infections in Neutropenic Patients Treated for Hematologic Malignancies: Evidence From a Meta-Analysis of 3,597 Patients J. Clin. Oncol., December 15, 2003; 21(24): 4615 - 4626. [Abstract] [Full Text] [PDF] W. G. Nichols Management of Infectious Complications in the Hematopoietic Stem Cell Transplant Recipient J Intensive Care Med, November 1, 2003; 18(6): 295 - 312. [Abstract] [PDF] T. Fukuda, R. C. Hackman, K. A. Guthrie, B. M. Sandmaier, M. Boeckh, M. B. Maris, D. G. Maloney, H. J. Deeg, P. J. Martin, R. F. Storb, et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation Blood, October 15, 2003; 102(8): 2777 - 2785. [Abstract] [Full Text] [PDF] T. Fukuda, M. Boeckh, R. A. Carter, B. M. Sandmaier, M. B. Maris, D. G. Maloney, P. J. Martin, R. F. Storb, and K. A. Marr Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning Blood, August 1, 2003; 102(3): 827 - 833. [Abstract] [Full Text] [PDF] M. Mielcarek, P. J. Martin, W. Leisenring, M. E. D. Flowers, D. G. Maloney, B. M. Sandmaier, M. B. Maris, and R. Storb Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation Blood, July 15, 2003; 102(2): 756 - 762. [Abstract] [Full Text] [PDF] D. J. Winston, R. T. Maziarz, P. H. Chandrasekar, H. M. Lazarus, M. Goldman, J. L. Blumer, G. J. Leitz, and M. C. Territo Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial Ann Intern Med, May 6, 2003; 138(9): 705 - 713. [Abstract] [Full Text] [PDF] O. A. Cornely, A. J. Ullmann, and M. Karthaus Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies Blood, May 1, 2003; 101(9): 3365 - 3372. [Abstract] [Full Text] [PDF] K. A. Marr, R. A. Carter, M. Boeckh, P. Martin, and L. Corey Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors Blood, December 15, 2002; 100(13): 4358 - 4366. [Abstract] [Full Text] [PDF] C. Junghanss, M. Boeckh, R. A. Carter, B. M. Sandmaier, M. B. Maris, D. G. Maloney, T. Chauncey, P. A. McSweeney, M.-T. Little, L. Corey, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study Blood, March 15, 2002; 99(6): 1978 - 1985. [Abstract] [Full Text] [PDF] D. Kaufman, R. Boyle, K. C. Hazen, J. T. Patrie, M. Robinson, and L. G. Donowitz Fluconazole Prophylaxis against Fungal Colonization and Infection in Preterm Infants N. Engl. J. Med., December 6, 2001; 345(23): 1660 - 1666. [Abstract] [Full Text] [PDF] K. M. Sullivan, C. A. Dykewicz, D. L. Longworth, M. Boeckh, L. R. Baden, R. H. Rubin, and K. A. Sepkowitz Preventing Opportunistic Infections After Hematopoietic Stem Cell Transplantation: The Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and Beyond Hematology, January 1, 2001; 2001(1): 392 - 421. [Abstract] [Full Text] [PDF]

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020